SLC2A1 and neoplasm: While the general application of GLUT1 inhibitors including diclofenac (DC) and siRNA often brings systemic energy metabolism disorders.[15] Therefore, it is also highly desired to locally suppress the expression of GLUT1 on tumor cells.